Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Pressure Biosciences Inc PBIO

Pressure BioSciences, Inc. is engaged in providing broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company's enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular... see more

PINL:PBIO - Post Discussion

Pressure Biosciences Inc > Pressure BioSciences Discusses Launch of Early Access
View:
Post by AveragePenny on Jun 01, 2022 11:46am

Pressure BioSciences Discusses Launch of Early Access

Mr. Copley inquired further: "We have certainly been hearing and want to learn more about the successful launch of your UST Early Access Program. Please explain!"

"UST, our latest platform technology innovation, is now being introduced into its first commercial applications. UST puts oil and water emulsions under extremely high pressures, which drive the emulsions through a dynamically controlled valve with a nano-gap orifice to produce intense and precise shearing down to vanishingly small nanoemulsion oil droplet sizes," said Mr. Schumacher. "We have seven UST issued patents so far, including two in the United States, with many more expected to follow."

Mr. Schumacher continued: "The oil in these emulsions typically contains the valuable active ingredients, which could be a pharmaceutical or a nutraceutical, a functional cosmetic ingredient, or important food and beverage nutrients. And in UST-produced nanoemulsions with extremely tiny and controlled droplet sizes, these components suddenly become nearly 100% bioavailable, allowing the body to absorb them much more efficiently, while the solution also becomes visibly transparent - offering heightened smell, taste, and texture benefits. An additional benefit is that the intense shear forces of UST also shred many microbial contents, providing enormously extended room temperature and cold-chain shelf life and stability for foods, beverages, and many other products."

"Due to pressing demand, we recently decided to announce an Early Access Program for the UST platform to serve a handful of companies impatient to wait for our full commercial release planned for the 4th Quarter of 2022," Mr. Schumacher explained. "We are choosing four to five companies over the next few weeks and months, and our team will work with them to lead the way in showing the world what we can accomplish together with our revolutionary Ultra Shear Technology platform," he continued.

Mr. Copley focused further: "Who is Safer Medical and why did you choose them for the first customer of your UST Early Access Program?"

"Safer Medical is a small, innovative company in Montana specializing in personal care products. It is led by a former Vietnam veteran who basically wants to give back," shared Mr. Schumacher, adding that Safer Medical approached Pressure BioSciences with a CBD product they had designed that needed improved bioavailability. "We began with some initial demos, and then started working with them and we have dramatically improved their product by changing the formulation and making it into an immediately penetrating and highly bioavailable nanoemulsion by using Ultra Shear Technology."

"We decided that we would bring Safer Medical on as our first customer," continued Mr. Schumacher, "as the initial scale for this product would be a good fit with our pre-launch UST processing capacity. We're finishing the formulation work now, and will then proceed into pilot runs, for market testing. We plan that by the fourth quarter we will start making vials for the commercial sale of this product," he said. "We anticipate this will be the first commercial product on the market that uses Ultra Shear Technology."

https://www.newsfilecorp.com/release/126142

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities